Does l-arginine supplementation play a role in cerebral small vessels disease? Implication in the treatment of leukoaraiosis

Medical Hypotheses

Volumn 77, Issue 4, 2011, Pages 671-673

  Calabro R S ^a   Gervasi, G ^a   Bramanti, P ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE;

ANGINA PECTORIS; ARTERIOLOSCLEROSIS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HUMAN; INTERMITTENT CLAUDICATION; LEUKOARAIOSIS; LIFE EXPECTANCY; MELAS SYNDROME; NONHUMAN;

ARGININE; CEREBROVASCULAR CIRCULATION; HUMANS; LEUKOARAIOSIS; MODELS, THEORETICAL;

ANGINA;

EID: 80052628813     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.07.012     Document Type: Article

References (35)

1. Böger R.H., Bode-Böger S.M. The clinical pharmacology of l-arginine. Annu Rev Pharmacol Toxicol 2001, 41:79-99.
2. Coman D., Yaplito-Lee J., Boneh A. New indications and controversies in arginine therapy. Clin Nutr 2008, 27:489-496.
3. Böger R.H. l-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?. Curr Opin Clin Nutr Metab Care 2008, 11:55-61.
4. Appleton J. Arginine: clinical potential of a semi-essential amino. Altern Med Rev 2002, 7:512-522.
5. Koga Y., Akita Y., Nishioka J., et al. MELAS and l-arginine therapy. Mitochondrion 2007, 133-139.
6. Koga Y., Akita Y., Junko N., et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology 2006, 66:1766-1769.
7. de Leeuw F.E., de Groot J.C., Achten E., et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001, 70:9-14.
8. Pantoni L. Leukoaraiosis: from an ancient term to an actual marker of poor prognosis. Stroke 2008, 39:1401-1403.
9. Buyck J.F., Dufouil C., Mazoyer B., et al. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. Stroke 2009, 40:2327-2331.
10. Prins N.D., van Dijk E.J., den Heijer T., et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004, 61:1531-1534.
11. Inzitari D., Pracucci G., Poggesi A., et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis, disability) study cohort. BMJ 2009, 339:b2477.
12. Baezner H., Blahak C., Poggesi A., et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology 2008, 70:935-942.
13. Jokinen H., Kalska H., Ylikoski R., et al. Longitudinal cognitive decline in subcortical ischemic vascular disease-the LADIS Study. Cerebrovasc Dis 2009, 27:384-391.
14. Smith E.E. Leukoaraiosis and stroke. Stroke 2010, 41:S139-S143.
15. Szolnoki Z. Pathomechanism of laukoarariosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). Neuromol Med 2007, 9:21-34.
16. Wardlaw J.M., Sandercock P.A., Dennis M.S., Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?. Stroke 2003, 34:806-812.
17. Turner S.T., Fornage M. Genetics of leukoaraiosis. J Stroke Cerebrovasc Dis. 2002, 11:241-251.
18. Moncada S., Higgs E.A. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006, 176(Pt. 1):213-254.
19. Helenius J., Tatlisumak T. Treatment of leukoaraiosis: a futuristic view. Curr Drug Targets 2007, 8:839-845.
20. Soinne L., Helenius J., Saimanen E., et al. Brain diffusion changes in carotid occlusive disease treated with endarterectomy. Neurology 2003, 61:1061-1065.
21. Bès A., Orgogozo J.M., Poncet M., et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999, 6:313-322.
22. Pantoni L., Carosi M., Amigoni S., Mascalchi M., Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996, 19:497-506.
23. Böger R.H. The pharmacodynamics of l-arginine. J Nutr 2007, 137:1650S-1655S.
24. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog Neurobiol 2001, 64:365-391.
25. Toda N., Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol Rev 2003, 55:271-324.
26. Toda N., Ayajiki K., Tanaka T., Okamura T. Preganglionic and postganglionic neurons responsible for cerebral vasodilation mediated by nitric oxide in anesthetized dogs. J Cereb Blood Flow Metab 2000, 20:700-708.
27. Melikian N., Seddon M.D., Casadei B., Chowienczyk P.J., Shah A.M. Neuronal nitric oxide synthase and human vascular regulation. Trends Cardiovasc Med 2009, 19:256-262.
28. O'Kane R.L., Viña J.R., Simpson I., Zaragozá R., Mokashi A., Hawkins R.A. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am J Physiol Endocrinol Metab. 2006, 291:E412-E419.
29. Briley D.P., Haroon S., Sergent S.M., Thomas S. Does leukoaraiosis predict morbidity and mortality?. Neurology 2000, 54:90-94.
30. Pantoni L., Poggesi A., Basile A.M., et al. Leukoaraiosis predicts hidden global functioning impairment in nondisabled older people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. J Am Geriatr Soc 2006, 54:1095-1101.
31. Inzitari D., Cadelo M., Marranci M.L., Pracucci G., Pantoni L. Vascular deaths in elderly neurological patients with leukoaraiosis. J Neurol Neurosurg Psychiatry 1997, 62:177-181.
32. Palumbo V., Boulanger J.M., Hill M.D., Inzitari D., Buchan A.M. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007, 68:1020-1024. CASES Investigators.
33. Wong T.Y., Klein R., Sharrett A.R., et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 2002, 288:67-74.
34. Görner A., Lemmens R., Schrooten M., Thijs V. Is leukoaraiosis on CT an accurate surrogate marker for the presence of microbleeds in acute stroke patients?. J Neurol 2007, 254:284-289.
35. Pantoni L., Basile A.M., Pracucci G., et al. Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology 2005, 24:51-62.